Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China DOI Creative Commons
Guanghui Ma,

Guohou Xu,

Haixia Huang

и другие.

Diabetology & Metabolic Syndrome, Год журнала: 2025, Номер 17(1)

Опубликована: Янв. 16, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the presence of at least one cardiovascular (CVD) risk factor, underscoring its potential to elevate CVD in affected individuals. However, evidence linking MASLD subclinical coronary atherosclerosis remains scarce, and further investigations are necessary elucidate independent role varying severities as a factor. This study analyzed 7,507 participants aged ≥ 40 who underwent comprehensive health evaluations Shanghai Health Medical Center. Logistic regression analysis was utilized explore relationship between severity artery calcification (CAC). Correlation performed assess association CAC staging. After adjusting for established factors, showed significant with CAC, which intensified increasing severity. Among individuals hypertension, markedly correlated CAC. In contrast, non-hypertensive participants, only moderate severe were significantly associated while mild demonstrated no notable link, even after adjustment factors. Moreover, correlation revealed positive staging, indicating that higher aligned more advanced stages. highlighted independently atherosclerosis, irrespective traditional an urban eastern Chinese population without prior history atherosclerosis. The strongest associations observed MASLD, emphasizing importance assessing stratification.

Язык: Английский

Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Язык: Английский

Процитировано

36
Steatotic liver disease DOI
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis

и другие.

The Lancet, Год журнала: 2024, Номер 404(10464), С. 1761 - 1778

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

28
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus DOI
Xufen Zeng, Krista A Varady, Xiangdong Wang

и другие.

Metabolism, Год журнала: 2024, Номер 161, С. 156028 - 156028

Опубликована: Сен. 11, 2024

Язык: Английский

Процитировано

23
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment DOI Creative Commons
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri

и другие.

The Lancet Diabetes & Endocrinology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

19
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025 DOI
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo

и другие.

Diabetes Care, Год журнала: 2024, Номер 48(Supplement_1), С. S59 - S85

Опубликована: Дек. 9, 2024

Язык: Английский

Процитировано

18
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD DOI Creative Commons
Yasaman Vali, Anne‐Marieke van Dijk, Jenny Lee

и другие.

Liver International, Год журнала: 2025, Номер 45(2)

Опубликована: Янв. 24, 2025

ABSTRACT Background and Aims The performance of non‐invasive liver tests (NITs) is known to vary across settings subgroups. We systematically evaluated whether the three NITs in detecting advanced fibrosis patients with metabolic dysfunction‐associated steatotic disease (MASLD) varies age, sex, body mass index (BMI), type 2 diabetes mellitus (T2DM) status or enzymes. Methods Data from 586 adult LITMUS Metacohort participants histologically characterised MASLD were included. diagnostic Fibrosis‐4 Index (FIB‐4), enhanced (ELF) vibration‐controlled transient elastography stiffness measurement (VCTE LSM) was evaluated. Performance expressed as area under receiver operating characteristics curve (AUC). Thresholds for (≥F3) calculated each NIT fixed (high) sensitivity, specificity predictive values. Results Differences AUC between all subgroups small statistically not significant, indicating comparable ≥F3, irrespective these clinical factors. However, different thresholds needed achieve same level accuracy test. For example, a sensitivity specificity, higher T2DM. Effects age enzymes less pronounced. Conclusions selected does substantially characteristics. have be values respective Large prospective studies are called study considering multiple patient

Язык: Английский

Процитировано

3
Flavonoids for gastrointestinal tract local and associated systemic effects: A review of clinical trials and future perspectives DOI Creative Commons
Xiaopeng Li, Enjun Xie,

Shumin Sun

и другие.

Journal of Advanced Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Flavonoids are naturally occurring dietary phytochemicals with significant antioxidant effects aside from several health benefits. People often consume them in combination other food components. Compiling data establishes a link between bioactive flavonoids and prevention of diseases animal models, including cardiovascular diseases, diabetes, gut dysbiosis, metabolic dysfunction-associated steatotic liver disease (MASLD). However, numerous clinical studies have demonstrated the ineffectiveness contradicting rodent thereby challenging validity using as supplements. This review provides perspective to emphasize effective roles well summarize their specific mechanisms animals briefly. First, this offers an in-depth elucidation processes within human, encompassing small, large intestine, liver. Furthermore, comprehensive overview various functions gastrointestinal tract, hindering breakdown assimilation macronutrients, such polysaccharides lipids, regulating hormone secretion inhibition mineral iron absorption. In unabsorbed major portion interact flora leading biotransformation. Once absorbed circulated bloodstream, or metabolites exert beneficial systemic effects. Lastly, we examine protective disorders, endothelial dysfunction, MASLD, disease, obesity, hyperlipidemia, insulin resistance. conclusion, outlines safety future prospects field health, especially syndrome (MetS).

Язык: Английский

Процитировано

2
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease DOI

Shixuan Jiao,

Qiang Ren,

Lianru Chen

и другие.

Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Янв. 24, 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease driven by diverse metabolic and inflammatory pathways. Farnesoid X receptor (FXR) promising target for MASH due to its role in bile acid lipid metabolism, while HSD17B13 regulates liver droplet homeostasis. However, the existing inhibitors have several druglike property challenges common phenolic structure, key pharmacophore inhibitor. In this study, two-round high-throughput screening was performed identify FXR agonist 2 as nonphenolic The multiparameter structural optimization led discovery of dual FXR/HSD17B13 modulator 6, with high selectivity, tissue distribution, suitable pharmacokinetic properties, safety profiles. Moreover, even at lower dose, compound 6 exerted better therapeutic effect than obeticholic (OCA) multiple models. With attractive pharmacological activity profiles, worthy further evaluation novel anti-MASH agent.

Язык: Английский

Процитировано

2
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Children with Obesity: An Obesity Medicine Association (OMA) and Expert Joint Perspective 2025 DOI Creative Commons

Jennifer Panganiban,

Mohit Kehar, Samar H. Ibrahim

и другие.

Obesity Pillars, Год журнала: 2025, Номер 14, С. 100164 - 100164

Опубликована: Фев. 1, 2025

This Obesity Medicine Association (OMA) Expert Joint Perspective examines steatotic liver disease (SLD), which is composed of metabolic dysfunction-associated (MASLD), and steatohepatitis (MASH) in children with obesity. The prevalence obesity increasing, rates have tripled since 1963 from 5 % to now 19 US affected 2018. MASLD, the most common seen children, can be a precursor development Type 2 Diabetes (T2DM) primary reason for transplant listing young adults. We must vigilant prevention treatment MASLD childhood prevent further progression. joint clinical perspective based upon scientific evidence, peer expertise. medical literature was reviewed via PubMed search appropriate articles were included this review. work formulated collaboration eight hepatologists/gastroenterologists expertise two physicians OMA. authors who are experts field, determined sentinel questions often asked by clinicians regarding They created consensus guideline on screening, diagnosis, associated children. comorbidity increasing problem that needs addressed urgently. It well known chronic continue these diseases as adults, leads reduced life expectancy, quality life, healthcare financial burden. paper recommend healthy weight reduction not only through lifestyle modification but pharmacotherapy bariatric surgery. Therefore, guidance reviews available therapies achieve reverse progressive fibrosis, disease.

Язык: Английский

Процитировано

2
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot DOI
Eda Kaya,

Wing‐Kin Syn,

Paul Manka

и другие.

Current Opinion in Gastroenterology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 14, 2025

Purpose of review Obesity and type 2 diabetes mellitus (T2DM) are significant global health challenges, closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in treating T2DM obesity, but their potential for managing MASLD is still being explored. This aims examine the current progress using GLP-1RAs treatment evaluate emerging dual triple hormonal as future therapeutic options. Recent findings been effective controlling blood sugar levels, promoting weight loss, improving cardiovascular kidney function. Furthermore, they benefits function patients with MASLD. GLP-1, a key incretin hormone, influences glucose metabolism, appetite, insulin sensitivity while affecting gastric emptying potentially reducing fat deposition liver. developments include various formulations different administration dosing options, expanding use. Summary become central management T2DM, possibly due ability lower HbA1c, aid reduction, provide protection. As research continues, next evolution incretin-based therapies, offering promising new strategies addressing future.

Язык: Английский

Процитировано

2